Pfizer has formed a multiyear collaboration with Nodality to use the latter’s single cell network profiling (SCNP) technology as a tool to streamline the development of new compounds for autoimmune diseases, beginning with lupus. Pfizer also has the option to use Nodality's technology, which was licensed from Stanford University, to develop novel companion diagnostics. Pfizer Venture Investments has been an investor in Nodality since 2008.